Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy

Transplantation

Volumn 76, Issue 9, 2003, Pages 1326-1330

  Henne, Thomas ^a   Latta, Kay ^a   Strehlau, Juergen ^a   Pape, Lars ^a   Ehrich, Jochen H H ^a   Offner, Gisela ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ARTICLE; CHILD; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GLOMERULUS FILTRATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TUBULE DISORDER; MALE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; VASCULAR DISEASE;

CHILD; CHRONIC DISEASE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 0242408495     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000088664.77589.F0     Document Type: Article

References (30)

1. Laine J, Holmberg C, Häyry P. Chronic rejection and late renal allograft dysfunction. Pediatr Nephrol 1996; 10: 221.
2. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783.
3. Tullius SG, Tilney NL. Both alloantigen-dependent and independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
4. Chavers BM, Kim EM, Matas AJ, et al. Causes of kidney allograft loss in a large pediatric population at a single center. Pediatr Nephrol 1994; 8: 57.
5. Offner G, Latta K, T Hoyer, et al. Kidney transplanted children come of age. Kidney Int 1999; 55: 1509.
6. Mihatsch MJ, Nickeleit V, Gudat F. Morphologic criteria of chronic renal allograft rejection. Transplant Proc 1999; 31: 1295.
7. Häyry P. Chronic rejection: risk factors, regulation and possible sites of therapeutic intervention. Transplant Proc 1998; 30: 2407.
8. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655.
9. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945.
10. Kliem V, Boeck A, Eisenberger U, et al. Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single center experience in 40 patients. Transplant Proc 1999; 31: 1312.
11. Campistol JM, Mazuecos A, Segura J, et al. Mycophenolate mofetil slows the decline of renal function in patients with biopsy proven chronic rejection: a collaborative pilot study. Transplant Proc 1999; 31: 2267.
12. Weir MR, Anderson L, Fink JC, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706.
13. Jirasiritham S, Sumethkul V, Mavichak V, et al. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil: a preliminary report of six months experience. Transplant Proc 1998; 30: 3576.
14. Glicklich D, Gupta B, Schurter-Frey G, et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. Transplantation 1998; 66: 398.
15. Weir MR. Chronic allograft nephropathy: nonimmunologic risk factors. Transplant Proc 1998; 30: 20S.
16. Filler G, Gellermann J, Zimmering M, et al. Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronic cyclosporine nephrotoxicity. Transplant Int 2000; 13: 201.
17. Ducloux D, Fournier V, Bresson T, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity. Transplantation 1998, 65: 1504.
18. Ferraris JR, Tambutti ML, Redal MA, et al. Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2003; 70: 297.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
20. Paul LC, Häyry P, Foegh M, et al. Diagnostic criteria for chronic rejection/ accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the fourth Alexis Carrel conference on chronic rejection and accelerated arteriosclerosis in transplanted organs. Transplant Proc 1993; 25: 2020.
21. Monaco AP, Burke JF, Ferguson, et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 1999; 33: 150.
22. Hoyer PF, Krohn HP, Offner G, et al. Renal function after kidney transplantation in children: a simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Transplantation 1987; 43: 489.
23. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 1998; 9: 1511.
24. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100.
25. Kasiske BL, Heim-Duthoy KL, Tortorice KL, et al. The variable nature of chronic declines in renal allograft function. Transplantation 1991; 51: 330.
26. Henne T, Offner G, Latta K, et al. Impact of MMF on CAN in children. Am J Transplant 2001; 1: 150.
27. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate Mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722.
28. Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil: mechanism of action and effects in transplantation. Transplant Rev 1993; 7: 129.
29. Abrass CK, Berfield AK, Stehman-Breen C, et al. Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies. Am J Kidney Dis 1999; 33: 11.
30. Butani L, Palmer J, Baluarte HJ, et al. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 1999; 68: 83.